SOURCE: Novo Nordisk A/S

September 03, 2008 05:18 ET

Holding(s) in Company

BAGSVAERD, DENMARK--(Marketwire - September 3, 2008) - Major shareholder notification


In accordance with Section 29 of the Securities Trading Act, Novo Nordisk hereby reports that The Capital Group Companies on 29 August 2008 informed Novo Nordisk that the voting rights attributable to their shareholding in Novo Nordisk are now below the threshold of 5% The Capital Group Companies now holds 63,668,444 B shares of DKK 1 equal to 10.04% of the total share capital in Novo Nordisk, corresponding to 3.98% of the voting rights.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:                          Investors:

Elin K Hansen                   Mads Veggerby Lausten
Tel (direct): (+45) 4442 3450   Tel (direct): (+45) 4443 7919
ekh@novonordisk.com             mlau@novonordisk.com

                                Hans Rommer
                                Tel (direct): (+45) 4442 4765
                                hrmm@novonordisk.com
In North America:
Sean Clements
Tel (direct): (+1) 609 514 8316
secl@novonordisk.com

Company Announcement no 55 / 2008





Copyright © Hugin AS 2008. All rights reserved.

Contact Information